# Regeneron **Source:** https://geo.sig.ai/brands/regeneron **Vertical:** Life Sciences & BioTech **Subcategory:** Biopharmaceuticals **Tier:** Leader **Website:** regeneron.com **Last Updated:** 2026-04-14 ## Summary Tarrytown NY biopharma giant; creator of Dupixent (>$14B revenue), Eylea, and Kevzara. Velocity Genome platform drives fast antibody and bispecific drug discovery. ## Company Overview Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized mouse technology that dramatically accelerates the discovery of human antibodies—and has used it to produce multiple best-in-class biologics across inflammatory, oncologic, and eye diseases.\n\nRegeneron's commercial portfolio is anchored by Dupixent (dupilumab), developed with Sanofi, which has become one of the best-selling drugs globally with over $14 billion in 2024 revenues, treating atopic dermatitis, asthma, COPD, and other type-2 inflammatory conditions. Additional key products include Eylea (aflibercept) for macular degeneration and PRALUENT for cardiovascular cholesterol lowering. The company's bispecific antibody pipeline, cancer vaccines in collaboration with BioNTech, and gene therapy programs represent its next growth wave.\n\nRegeneron reported over $14 billion in annual revenue in 2024 and maintains a world-class science culture, consistently ranking among the top companies for R&D productivity and employee satisfaction. Its Tarrytown campus houses more than 10,000 employees and remains a leading independent US biopharmaceutical innovator. ## Frequently Asked Questions ### What is Dupixent and why is it important? Dupixent is Regeneron's blockbuster biologic for type-2 inflammatory diseases like atopic dermatitis and asthma, generating over $14 billion in 2024 revenue and approved in 7+ indications. ### What is the Velocimmune platform? Velocimmune is Regeneron's proprietary humanized mouse technology for rapidly generating fully human therapeutic antibodies, underpinning most of its drug pipeline. ### What is Regeneron's pipeline focus beyond Dupixent? Regeneron is advancing bispecific antibodies, an mRNA cancer vaccine collaboration with BioNTech, gene therapy programs, and a next-generation Eylea HD formulation. ### Who founded Regeneron and when? Regeneron was founded in 1988 by Leonard Schleifer (CEO) and George Yancopoulos (President and Chief Scientific Officer) — two scientists who shared a vision of building a fully integrated pharmaceutical company grounded in rigorous science. Both remain in their leadership roles today, an unusual continuity for a major biotech. ### What other drugs has Regeneron commercialized beyond Dupixent? Beyond Dupixent, Regeneron's commercial portfolio includes EYLEA (aflibercept) for wet AMD and diabetic eye disease, Praluent (alirocumab) for LDL cholesterol reduction, Kevzara (sarilumab) for rheumatoid arthritis, Libtayo (cemiplimab) for skin cancers and lung cancer, and Inmazeb (atoltivimab) for Ebola — demonstrating breadth across immunology, ophthalmology, and oncology. ### How does Regeneron's REGN-COV antibody program demonstrate its platform? Regeneron developed REGEN-COV (casirivimab/imdevimab), a COVID-19 antibody cocktail, in record time during the pandemic using the Velocimmune platform — generating high-affinity human antibodies in months rather than years. This demonstrated that Regeneron's infrastructure could respond rapidly to novel pathogen threats. ### What is Regeneron's financial scale? Regeneron is a large-cap biopharmaceutical company with revenues exceeding $14 billion in 2024, driven primarily by Dupixent's global sales through the Sanofi partnership. The company trades on NASDAQ under the ticker REGN and has a market capitalization in the range of $50-80 billion depending on market conditions. ### What is the Sanofi partnership and why is it important? Regeneron and Sanofi co-develop and co-commercialize Dupixent globally under a long-standing collaboration agreement. Sanofi handles global sales and marketing in most markets, sharing costs and profits with Regeneron. This partnership gave Regeneron the commercial infrastructure to launch a global blockbuster without building its own worldwide sales force. ### What is Regeneron's history and when was it founded? Regeneron was founded in 1988 by George Yancopoulos and P. Roy Vagelos (later Leonard Schleifer as CEO) in Tarrytown, New York. It spent over a decade in R&D before its first commercial success — VEGF Trap (Eylea) for eye disease — transforming it into one of the most valuable biopharmaceutical companies in the world. ### How significant is Dupixent to Regeneron's finances? Dupixent (dupilumab), co-commercialized with Sanofi, generated over $14 billion in net sales in 2024 and is approved for 7+ indications including atopic dermatitis, asthma, eosinophilic esophagitis, prurigo nodularis, and COPD — making it one of the best-selling drugs in pharmaceutical history and the primary driver of Regeneron's profitability. ### What is Eylea and how does it contribute to Regeneron's business? Eylea (aflibercept) is an anti-VEGF injection for age-related macular degeneration and diabetic eye disease. Eylea HD (higher dose, less frequent dosing) was approved in 2023. Together they represent Regeneron's ophthalmology franchise alongside newer competitors. ### What antibody therapies beyond Dupixent does Regeneron have? Regeneron markets Kevzara (rheumatoid arthritis), Libtayo (PD-1 inhibitor for certain cancers), Praluent (LDL cholesterol), Inmazeb (Ebola), and is developing bispecific antibodies for oncology including combinations targeting EGFR, MET, and BCMA across multiple tumor types. ### What is Regeneron Genetics Center? The Regeneron Genetics Center is the company's large-scale human genetics research operation, having sequenced over 2 million exomes linked to de-identified health records. It identifies genetic variants associated with disease to guide drug discovery — a proprietary database that gives Regeneron a significant competitive advantage in target identification. ## Tags b2b, global, public, enterprise, healthtech, manufacturing, fortune500 --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*